Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Not Recruiting

Trial ID: NCT04551430


The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.

Official Title

A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Stanford Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo

Professor of Medicine (Oncology)


Inclusion Criteria:

   - Histologically or cytologically confirmed soft tissue sarcoma that is metastatic or

   - Measurable disease defined as lesions that can be accurately measured in at least one
   dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by
   chest x-ray, or ≥ 10 mm with calipers by clinical exam.

   - Refractory to at least one and no more than two lines of therapy, with progression on
   last line of therapy. Neoadjuvant or adjuvant therapy completed more than one year
   prior does not count towards these two lines of therapy. Individuals with alveolar
   soft part sarcoma may enroll without being refractory to at least one line of
   chemotherapy. Any inappropriate therapies (ie hormonal therapies) should be discussed
   with the PI to determine if they are to be counted toward the two lines of therapy.

   - At least 18 years of age.

   - ECOG performance status ≤ 1

   - Normal bone marrow and organ function as defined below:

      - Absolute neutrophil count ≥ 1,500/mm3 without granulocyte colony-stimulating
      factor support

      - White blood cell count ≥ 2,000/mm3

      - Platelets ≥ 100,000/mm3 without transfusion

      - Hemoglobin ≥ 9.0 g/dL

      - Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease, ≤ 3.0 x IULN)

      - AST(SGOT), ALT(SGPT), and alkaline phosphatase (ALP) ≤ 3.0 x IULN; ALP ≤ 5.0 x
      IULN with documented bone metastases

      - Serum albumin ≥ 2.8 g/dl.

      - Serum creatinine ≤ 1.5x IULN or calculated creatinine clearance ≥ 40 mL/min by

      - Urine protein/creatinine ration (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)

      - PT/INR or PTT < 1.3 x IULN (within 7 days before first dose of study treatment,
      if not receiving any anticoagulation therapy)

   - Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms (by ECG
   within 14 days before the first dose of study treatment).

   - Lesion amenable to biopsy for assessment of PD-L1 expression if no archival tissue is

   - Recover to baseline or ≤ grade 1 from toxicities related to any prior treatments,
   unless AE(s) are clinically non-significant and/or stable on supportive therapy.

   - The effects of cabozantinib on the developing human fetus are unknown. For this
   reason, women of childbearing potential and men must agree to use adequate
   contraception (hormonal or barrier method of birth control, abstinence) prior to study
   entry, for the duration of study participation, and for 5 months after the last dose
   of study treatment. Should a woman become pregnant or suspect she is pregnant while
   participating in this study, she must inform her treating physician immediately. Men
   treated or enrolled on this protocol must also agree to use adequate contraception
   prior to the study, for the duration of the study, and for at least 7 months after the
   last dose of study treatment.

   - Ability to understand and willingness to sign an IRB approved written informed consent
   document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

   - Translocation-driven sarcoma except for ASPS

   - Previous treatment with cabozantinib or a PD-1 inhibitor (eg, cemiplimab, nivolumab,
   pembrolizumab), PD-L1 inhibitor (eg, atezolizumab, avelumab, durvalumab), or CTLA-4
   inhibitor (eg, ipilimumab).

   - A history of other malignancy with the exception of malignancies for which all
   treatment was completed at least 2 years before registration and the patient has no
   evidence of disease. Exceptions include basal cell or squamous cell carcinoma of the
   skin which were treated with local resection only or carcinoma in situ of the cervix,
   or other tumors discussed with the study PI.

   - Currently receiving any other investigational agents.

   - Known brain metastases. Patients with known brain metastases must be excluded from
   this clinical trial because of their poor prognosis and because they often develop
   progressive neurologic dysfunction that would confound the evaluation of neurologic
   and other adverse events.

   - Receipt of any type of small molecule kinase inhibitor (including investigational
   kinase inhibitor) within 2 weeks before first dose of study treatment.

   - Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy
   (including investigational) within 4 weeks before first dose of study treatment.

   - Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin
   inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet
   inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:

      - Prophylactic use of low-dose aspirin for cardio-protection (per local applicable
      guidelines) and low dose low molecular weight heparins (LMWH).

      - Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors
      rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who
      are on a stable dose of the anticoagulant for at least 1 week before first dose
      of study treatment without clinically significant hemorrhagic complications from
      the anticoagulation regimen or the tumor.

   - Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy
   within 4 weeks before first dose of study treatment. Systemic treatment with
   radionuclides within 6 weeks before the first dose of study treatment. Subjects with
   clinically relevant ongoing complications from prior radiation therapy are not

   - A history of allergic reactions attributed to compounds of similar chemical or
   biologic composition to cabozantinib, nivolumab, ipilimumab, or other agents used in
   the study.

   - Inability to swallow tablets.

   - The subject has uncontrolled, significant intercurrent or recent illness including,
   but not limited to, the following conditions:

      - Cardiovascular disorders:

         - Congestive heart failure New York Heart Association Class 3 or 4, unstable
         angina pectoris, serious cardiac arrhythmias.

         - Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm
         Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive

         - Stroke (including transient ischemic attack [TIA]), myocardial infarction
         (MI), or other ischemic event, or thromboembolic event (e.g., deep venous
         thrombosis, pulmonary embolism) within 6 months before first dose of study

            - Subjects with a diagnosis of incidental, subsegmental PE or DVT within
            6 months are allowed if stable, asymptomatic, and treated with
            anticoagulation for at least 1 week before first dose of study

      - Gastrointestinal (GI) disorders including those associated with a high risk of
      perforation or fistula formation:

         - The subject has evidence of tumor invading the GI tract, active peptic ulcer
         disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis,
         cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis,
         acute obstruction of the pancreatic duct or common bile duct, or gastric
         outlet obstruction.

         - Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal
         abscess within 6 months before first dose.

         - Note: Complete healing of an intra-abdominal abscess must be confirmed
         before first dose.

      - Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon
      (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary
      hemorrhage) within 12 weeks before first dose.

      - Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease

      - Lesions invading or encasing any major blood vessels.

      - Other clinically significant disorders that would preclude safe study

         - Serious non-healing wound/ulcer/bone fracture.

         - Uncompensated/symptomatic hypothyroidism.

         - Moderate to severe hepatic impairment (Child-Pugh B or C)

   - Any active, known, or suspected autoimmune disease Note: subjects with type I diabetes
   mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as
   vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not
   expected to recur in the absence of an external trigger are permitted to enroll.

   - Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily
   prednisone equivalent) or other immunosuppressive medications within 14 days of
   randomization Note: inhaled, intranasal, intra-articular, or topical steroids are
   permitted. Adrenal replacement steroid doses > 10 mg daily prednisone equivalent are
   permitted in the absence of active autoimmune disease. Transient short-term use of
   systemic corticosteroids for allergic conditions (e.g. contrast allergy) is also

   - Active infection requiring systemic treatment. Acute or chronic hepatitis B or C
   infection, known human immunodeficiency virus (HIV) or acquired immunodeficiency
   syndrome (AIDS)-related illness, or known positive test for tuberculosis infection

   - History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, or evidence of active pneumonitis on screening chest CT scan

   - Malabsorption syndrome

   - Requirement for hemodialysis or peritoneal dialysis

   - History of solid organ or allogeneic stem cell transplant.

   - Major surgery (e.g. laparoscopic nephrectomy, GI surgery removal or biopsy of brain
   metastasis) within 2 weeks before first dose of study treatment. Minor surgeries
   within 10 days before first dose of study treatment. Subjects must have complete wound
   healing from major surgery or minor surgery before first dose of study treatment.
   Patients with clinically relevant ongoing complications from prior surgery are not

   - Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
   pregnancy test within 15 days of study entry. Women of childbearing potential are
   defined as premenopausal females capable of becoming pregnant (i.e., females who have
   had any evidence of menses in the past 12 months, with the exception of those who had
   prior hysterectomy). However, women who have been amenorrheic for 12 or more months
   are still considered to be of childbearing potential if the amenorrhea is possibly due
   to prior chemotherapy, antiestrogens, low body weight, ovarian suppression, or other

   - Administration of a live, attenuated vaccine within 30 days prior to randomization.


drug: Cabozantinib

drug: Nivolumab

drug: Ipilimumab

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Behnaz (Parsien) Agahian

New Trial Alerts